Severe Mitral Stenosis Management

Auscultation Findings

The American Heart Association notes that severe mitral stenosis is characterized by a low-pitched diastolic rumbling murmur at the apex, an opening snap, and specific hemodynamic findings that guide management decisions including medical therapy, percutaneous mitral commissurotomy, or valve replacement 1, 2
The classic auscultatory finding is a low-pitched, rumbling diastolic murmur best heard at the apex with the bell of the stethoscope with the patient in the left lateral decubitus position 1
An opening snap (OS) follows the second heart sound (S2) and precedes the diastolic murmur, representing the sudden tensing of the valve leaflets 1
The interval between S2 and OS shortens as mitral stenosis severity increases, reflecting higher left atrial pressure 1
First heart sound (S1) is typically accentuated due to prolonged closure of the mitral valve from high left atrial pressure 1
In severe mitral stenosis, the diastolic murmur is longer in duration, extending throughout diastole 1
The murmur increases in intensity with maneuvers that increase cardiac output (exercise, squatting) or heart rate (amyl nitrite) 1, 3

The American College of Cardiology recommends that mitral valve area ≤1.5 cm² by planimetry or pressure half-time method is indicative of severe mitral stenosis 1
Mean transmitral pressure gradient typically >5-10 mmHg at normal heart rate 1
Diastolic pressure half-time ≥150 ms 1
Severe left atrial enlargement 1, 2
Elevated pulmonary artery systolic pressure >30 mmHg 1

The European Society of Cardiology suggests that diuretics may be used for symptom relief when edema or pulmonary congestion is present 2
Heart rate control with beta-blockers or calcium channel blockers in patients with atrial fibrillation to prolong diastolic filling time 2
Digoxin may be used specifically for heart rate control in patients with atrial fibrillation 2
Anticoagulation is indicated in patients with a history of systemic embolism, dense spontaneous contrast in the left atrium on echocardiography, atrial fibrillation, or an enlarged left atrium (diameter >60 mL/m²) 2
Vitamin K antagonists are preferred over NOACs in patients with mitral stenosis and atrial fibrillation 2

Symptomatic severe mitral stenosis (NYHA class II-IV) with valve area ≤1.5 cm² 4, 2
Asymptomatic severe mitral stenosis with elevated pulmonary artery systolic pressure >50 mmHg, new-onset atrial fibrillation, or high risk of thromboembolism (history of embolism, dense spontaneous contrast) 2

Percutaneous mitral balloon commissurotomy (PMC) is the first-line intervention for patients with favorable valve morphology (minimal calcification, no significant mitral regurgitation) 4, 2
Surgical options include open mitral commissurotomy for patients with favorable valve anatomy but unsuitable for PMC, and mitral valve replacement for patients with unfavorable valve anatomy (heavy calcification, significant subvalvular fusion) 4

Echocardiographic assessment every 2-3 years for asymptomatic severe mitral stenosis 2
More frequent monitoring (yearly) for patients with very severe stenosis or borderline hemodynamics 2
Clinical evaluation for development of symptoms, atrial fibrillation, or pulmonary hypertension 1, 2